Skip to main content

Table 2 Characteristics of relapsed patients in SACQ and SQCQ group when they relapsed

From: Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

  SACQ (56) SQCQ (29) p
Flare 56/170 (32.9%) 29/187 (15.5%) < 0.001
SLEDAI-2 K 6.0 (4.0, 8.0) 5.0 (2.5, 8.0) 0.036
Recurrence time (month)a 21.82 (13.39, 31.59) 26.43 (16.72, 41.97) 0.079
Dose of corticosteroidsb (mg) 5.0 (2.81, 7.5) 5.0 (0, 5.0) 0.082
Taking antimalarials 36/56 (64.3%) 17/29 (58.6%) 0.609
Taking immunosuppressants 23/56 (41.1%) 10/29 (34.5%) 0.555
  1. SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000
  2. aThe period from the time they reached the SACQ/SQCQ to the time of recurrence
  3. bCorticosteroid doses were converted to milligrams (mg) of prednisone equivalent